Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05310331
Other study ID # DONA1
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 27, 2022
Est. completion date June 27, 2024

Study information

Verified date March 2022
Source Peking Union Medical College Hospital
Contact Lei Li, M.D.
Phone 86-139-1198-8831
Email lileigh@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate the safety and tolerability of Donafenib combined with paclitaxel and platinum ± programmed death 1 monoclonal antibody (PD-1 antibody) in patients with recurrent cervical cancer.


Description:

This is a single center, non-randomized, open-label Phase II clinical study to investigate the efficacy and tolerability of Donafenib combined with paclitaxel and platinum ± PD-1 antibody in patients with recurrent cervical cancer. In total 20 patients will receive Donafenib (200mg, bid) combined with paclitaxel (135mg/m2) and cisplatin (creatinine clearance rate > 60ml/min, 50 mg/m2) or paclitaxel (175 mg/m2) and carboplatin AUC=5 (40ml/min < creatinine clearance rate < 60ml/min) ± PD-1 antibody every 3 weeks. Actual Study Start Date: March 27, 2022 Estimated Primary Completion Date: December 27, 2023 Estimated Study Completion Date: June 27, 2024 Arms There is only one arm, i.e., group of Donafenib combined with paclitaxel and platinum ± PD-1 antibody. Each treatment period was 21 days. Patients will be treated with 4-6 cycles of Donafenib plus TP or TC ± PD-1 antibody. After completion of the combination, patients will be maintained on Donafenib until disease progression or unacceptable toxicity occurs (up to 12 months) Donafenib was taken orally at 200 mg twice on an empty stomach (1 hour before or > 2 hours after meal) in the morning and evening of each administration day, with an interval of about 12 hours. Maintain the same dose until disease progression, death, toxicity intolerance, withdrawal of informed consent, initiation of new antineoplastic therapy, or termination of treatment for other reasons specified in the protocol, for a maximum of 12 months. Paclitaxel and platinum: If creatinine clearance rate > 60ml/min: on Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of paclitaxel 135 mg/m2plus cisplatin 50 mg/m2. If 40ml/min < creatinine clearance rate < 60ml/min:on Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of paclitaxel 175 mg/m2 plus carboplatin AUC=5. PD-1 antibody: PD-1 antibody is not mandatory, intravenous infusion on the first day of each cycle, every 3 weeks for a cycle until disease progression, death, toxicity intolerance, withdrawal of informed consent, initiation of new antitumor therapy, or termination of treatment for other reasons specified in the protocol, the longest treatment period is 12 months. The primary outcome measure is progression-free survival. The secondary outcome measures include overall survival, objective response rate, etc.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date June 27, 2024
Est. primary completion date December 27, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion criteria - Written informed consent obtained. - Age 18~75, female. - Histologically confirmed cervical squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma. - Patients with cervical cancer recurred for the first time, and did not receive any treatment after recurrence. - Patients must have measurable disease per RECIST 1.1. - ECOG performance status 0 or 1, expected lifetime = 3 months. - No targeted drugs containing VEGF were used before, including but not limited to anlotinib, apatinib, bevacizumab, etc. - Adequate organ function: - Absolute neutrophil count (ANC) = 1.5x109/L, Platelets = 100x109/L, Hemoglobin (Hb) = 90g/L, Bilirubin = 1.5 times the upper limit of normal, ALT/AST = 3x ULN (for patient with liver metastasis ALT/AST = 5x ULN), Serum bilirubin =1.5x ULN, Serum creatinine = 1.5 times the upper limit of normal, and creatinine clearance = 40ml/min (calculated by Cockcroft-Gault formula); International normalized ratio (INR) =1.5 Exclusion Criteria: - Histopathologic diagnoses of tumors other than squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma. - With second primary malignant diseases. - Pregnancy or children bearing potential. - With uncontrolled auto-immune diseases, interstitial pneumonia, ulcerative colitis, or patients who should receive long-term glucocorticoid treatment (>10mg/d prednisone). - With uncontrollable complications. - Conditions which impact on pill taking (dysphagia, chronic diarrhea, bowel obstruction). - Known hypersensitivity reaction to any of the study drugs or components. - Other unsuitable conditions determined by investigators. - Hepatitis B virus (HBV) >2000 IU/ml or DNA = 1×10^4/ml; or hepatitis C virus (HCV) RNA = 1×10^3/ml). - Has received a live vaccine within 4 weeks prior to the first dose of trial treatment. Note: Injection of inactivated viral vaccines against seasonal influenza are allowed. - Has pleural effusion and ascites that require punctured and drained. However, an exception includes patients with pleural effusion and ascites who have no symptoms. - Any other medical, psychiatric, or social condition deemed by the investigator to be likely to interfere with a subject's rights, safety, welfare, or ability to sign informed consent, cooperate, and participate in the study or would interfere with the interpretation of the results.

Study Design


Intervention

Combination Product:
Donafenib combined with paclitaxel and platinum ± PD-1 antibody
Patients will receive Donafenib (200mg, bid) combined with paclitaxel (135mg/m2) and cisplatin (creatinine clearance rate > 60ml/min, 50 mg/m2) or paclitaxel (175 mg/m2) and carboplatin AUC=5 (40ml/min < creatinine clearance rate < 60ml/min) ± PD-1 antibody every 3 weeks.

Locations

Country Name City State
China Lei Li Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Lei Li

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-Free Survival (PFS) PFS defined as the time the duration from date of enrollment to the first documented disease progression, or death due to any cause, whichever occurs first. 24 months
Secondary Overall survival Overall survival is defined as the duration from date of enrollment to the date of death from any cause. 36 months
Secondary Objective Response Rate (ORR) ORR is defined as the percentage of participants in the analysis population who have a complete or partial remission. 24 months
Secondary Duration of Response (DCR) DCR is defined as the percentage of participants in the analysis population who have a complete or partial remission, or stable disease (SD). 24 months
Secondary Adverse Events Adverse event (AE)?Treatment emergent adverse event (TEAE)?Serious adverse event (SAE). 24 months
See also
  Status Clinical Trial Phase
Completed NCT03652727 - FX vs. ECG Guidance for PICC Insertion N/A
Not yet recruiting NCT05856656 - Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer N/A
Active, not recruiting NCT02959541 - PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer N/A
Completed NCT00757094 - Safety and Feasibility of Fasting While Receiving Chemotherapy N/A
Recruiting NCT00797238 - DNA Repair Genes and Outcomes in Patients With Stage III NSCLC N/A
Not yet recruiting NCT05927857 - Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . Phase 1/Phase 2
Recruiting NCT04453826 - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Phase 3
Completed NCT04466332 - Comparison of Two ECG Guided PICC Insertion Techniques N/A
Not yet recruiting NCT04055038 - Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) Phase 2/Phase 3
Recruiting NCT03701607 - Effect of Chemotherapy on PD-L1 in NSCLC
Recruiting NCT04024241 - Medium Dose of Cytarabine and Mitoxantrone
Recruiting NCT06208436 - The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
Recruiting NCT05306301 - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients Phase 2
Active, not recruiting NCT02304640 - Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
Completed NCT02298972 - Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer N/A
Terminated NCT01249001 - Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents Phase 2
Recruiting NCT03089892 - A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy N/A
Recruiting NCT05125055 - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC Phase 2/Phase 3
Recruiting NCT04472403 - Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
Terminated NCT02982694 - Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer Phase 2